AstraZeneca Pharma India Limited (ASTRAZEN.BO)
INR 8061.9
(2.24%)
INR 8061.9
(2.24%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 10.78 Billion INR | 9.46% |
| 2022 | 9.84 Billion INR | 14.98% |
| 2021 | 8.56 Billion INR | 10.57% |
| 2020 | 7.74 Billion INR | 9.68% |
| 2019 | 7.06 Billion INR | 25.73% |
| 2018 | 5.61 Billion INR | 21.99% |
| 2017 | 4.6 Billion INR | 10.84% |
| 2016 | 4.15 Billion INR | -7.41% |
| 2015 | 4.48 Billion INR | 9.02% |
| 2014 | 4.11 Billion INR | -0.96% |
| 2013 | 4.15 Billion INR | 35.77% |
| 2012 | 3.06 Billion INR | -11.25% |
| 2011 | 3.44 Billion INR | 11.74% |
| 2010 | 3.08 Billion INR | 31.99% |
| 2009 | 2.33 Billion INR | -19.01% |
| 2008 | 2.88 Billion INR | 17.4% |
| 2007 | 2.45 Billion INR | 2.55% |
| 2006 | 2.39 Billion INR | 36.71% |
| 2005 | 1.75 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 FY | 10.78 Billion INR | 9.46% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 11.01 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 10.78 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 9.84 Billion INR | 14.98% |
| 2022 Q4 | 9.84 Billion INR | 0.0% |
| 2022 Q2 | 8.96 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 8.14 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 8.56 Billion INR | 0.0% |
| 2021 FY | 8.56 Billion INR | 10.57% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 7.2 Billion INR | 0.0% |
| 2020 Q4 | 7.74 Billion INR | 0.0% |
| 2020 FY | 7.74 Billion INR | 9.68% |
| 2019 FY | 7.06 Billion INR | 25.73% |
| 2019 Q2 | 6.46 Billion INR | 0.0% |
| 2019 Q4 | 7.06 Billion INR | 0.0% |
| 2018 Q4 | 5.61 Billion INR | 0.0% |
| 2018 Q2 | 4.87 Billion INR | 0.0% |
| 2018 FY | 5.61 Billion INR | 21.99% |
| 2017 FY | 4.6 Billion INR | 10.84% |
| 2017 Q2 | 4.35 Billion INR | 0.0% |
| 2017 Q4 | 4.6 Billion INR | 0.0% |
| 2016 Q2 | 3.93 Billion INR | 0.0% |
| 2016 FY | 4.15 Billion INR | -7.41% |
| 2016 Q4 | 4.15 Billion INR | 0.0% |
| 2015 Q2 | 3.83 Billion INR | 0.0% |
| 2015 FY | 4.48 Billion INR | 9.02% |
| 2015 Q4 | 4.48 Billion INR | 0.0% |
| 2014 Q2 | 3.77 Billion INR | 0.0% |
| 2014 FY | 4.11 Billion INR | -0.96% |
| 2014 Q4 | 4.11 Billion INR | 0.0% |
| 2013 Q2 | 3.6 Billion INR | 0.0% |
| 2013 FY | 4.15 Billion INR | 35.77% |
| 2013 Q4 | 4.15 Billion INR | 0.0% |
| 2012 Q4 | 3.06 Billion INR | 0.0% |
| 2012 FY | 3.06 Billion INR | -11.25% |
| 2011 Q4 | 3.44 Billion INR | 0.0% |
| 2011 FY | 3.44 Billion INR | 11.74% |
| 2010 FY | 3.08 Billion INR | 31.99% |
| 2009 FY | 2.33 Billion INR | -19.01% |
| 2008 FY | 2.88 Billion INR | 17.4% |
| 2007 FY | 2.45 Billion INR | 2.55% |
| 2006 FY | 2.39 Billion INR | 36.71% |
| 2005 FY | 1.75 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 83.275% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 97.608% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 62.18% |
| Granules India Limited | 55.2 Billion INR | 80.474% |
| Indoco Remedies Limited | 21.44 Billion INR | 49.736% |
| Achyut Healthcare Limited | 309.52 Million INR | -3382.881% |
| Ajanta Pharma Limited | 46.38 Billion INR | 76.759% |
| Alkem Laboratories Limited | 155.74 Billion INR | 93.078% |
| Alpa Laboratories Limited | 1.82 Billion INR | -490.307% |
| Brooks Laboratories Limited | 904.45 Million INR | -1091.911% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -40.895% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 11.191% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 97.218% |
| Eris Lifesciences Limited | 70.48 Billion INR | 84.706% |
| FDC Limited | 24.68 Billion INR | 56.321% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 92.492% |
| Gufic Biosciences Limited | 10.92 Billion INR | 1.328% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 7.474% |
| Ipca Laboratories Limited | 111.01 Billion INR | 90.289% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -396.609% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -505.04% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -614.547% |
| Laurus Labs Limited | 83.87 Billion INR | 87.146% |
| Lupin Limited | 239.97 Billion INR | 95.508% |
| Mankind Pharma Limited | 119.63 Billion INR | 90.989% |
| Medicamen Biotech Limited | 2.94 Billion INR | -266.026% |
| Medico Remedies Limited | 961.95 Million INR | -1020.666% |
| Megasoft Limited | 3.65 Billion INR | -194.624% |
| NATCO Pharma Limited | 69.06 Billion INR | 84.391% |
| Piramal Pharma Limited | 153.11 Billion INR | 92.959% |
| RPG Life Sciences Limited | 5.12 Billion INR | -110.195% |
| Sigachi Industries Limited | 6.94 Billion INR | -55.3% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 98.739% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 52.174% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -166.401% |
| Unichem Laboratories Limited | 31.69 Billion INR | 65.986% |
| Wanbury Limited | 3.43 Billion INR | -213.843% |
| Windlas Biotech Limited | 6.26 Billion INR | -72.152% |
| ZIM Laboratories Limited | 4.46 Billion INR | -141.266% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 96.318% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -109.31% |
| Divi's Laboratories Limited | 154.7 Billion INR | 93.031% |
| Hester Biosciences Limited | 6.62 Billion INR | -62.759% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -35.71% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -193.844% |
| Bal Pharma Limited | 3.2 Billion INR | -236.475% |
| Strides Pharma Science Limited | 58.39 Billion INR | 81.54% |
| Venus Remedies Limited | 6.26 Billion INR | -71.981% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 58.25% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 50.799% |
| Shilpa Medicare Limited | 30.93 Billion INR | 65.148% |
| Aarti Drugs Limited | 24.32 Billion INR | 55.68% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 51.968% |
| Suven Life Sciences Limited | 2.84 Billion INR | -278.385% |
| Ind-Swift Limited | 6.54 Billion INR | -64.717% |
| Valiant Laboratories Limited | 3.42 Billion INR | -214.581% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 73.01% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | 54.145% |
| Themis Medicare Limited | 5.66 Billion INR | -90.324% |
| Hikal Limited | 24.87 Billion INR | 56.656% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 92.842% |
| Sequent Scientific Limited | 15.4 Billion INR | 30.016% |
| Novartis India Limited | 9.24 Billion INR | -16.552% |
| Wockhardt Limited | 76.49 Billion INR | 85.906% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 90.665% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -2189.648% |
| Neuland Laboratories Limited | 18.32 Billion INR | 41.174% |
| Morepen Laboratories Limited | 12.93 Billion INR | 16.639% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -349.063% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -223.32% |